Arecor Therapeutics occupies an unusual niche on London's junior market: rather than hunting for wholly new molecules, it re-engineers medicines that already exist. The Cambridge-based group applies its Arestat formulation technology to make proteins and peptides more concentrated, more stable or easier to deliver. Over the past two years it's signed a US insulin-pump co-development pact, monetised royalty rights, and wound down a loss-making commercial arm.

The Quick Version

  • Arecor is an AIM-listed (AREC) formulation-science company applying its Arestat platform to diabetes, obesity and partnered specialty products.
  • Lead candidate AT278, an ultra-concentrated ultra-rapid insulin, completed Phase I and is advancing toward Phase 2 under a September 2025 co-development agreement with US pump maker Sequel Med Tech.
  • A September 2025 deal sold royalty and milestone rights on partnered programmes AT220 and AT292 to Ligand Pharmaceuticals for up to $11m, of which $7m was upfront.
  • The former commercial subsidiary Tetris Pharma was wound down from January 2025, refocusing the group on formulation development and licensing.
  • Cash and investments stood at £6.1m at FY2025 results, with management guiding a base-case runway into 2027.

What Arecor Actually Does

Arecor operates two complementary tracks: a proprietary clinical pipeline centred on next-generation insulins for pumps and automated insulin delivery systems, and a partnering engine applying Arestat to third-party molecules under formulation-development collaborations. Arestat is the intellectual heart — a proprietary formulation technology overcoming aggregation, instability, low solubility and cold-chain constraints, letting drugs become more concentrated, thermally stable or ready-to-use.

The Sequel Med Tech Deal, Explained

In September 2025, Arecor signed a co-development agreement with Sequel Med Tech, US developer of the twiist automated insulin delivery system. Both companies jointly fund the work needed to reach Phase 2 readiness for AT278, each committing up to $1.3m toward regulatory interactions, clinical-trial manufacturing and device-compatibility work — with intent to explore a broader commercialisation partnership for later phases, though that expanded deal remains an intention rather than a signed commitment.

AT278 is an ultra-concentrated (500 U/mL) ultra-rapid insulin for pump reservoirs; AT247 is a related ultra-rapid prandial insulin. Both completed Phase I with accelerated absorption relative to comparators — early pharmacokinetic findings, not proof of clinical benefit.

Monetising Royalties: The Ligand Deal

Alongside Sequel, Arecor sold financial rights on two partnered programmes to Ligand Pharmaceuticals — global royalty rights on AT220 (commercialised by an undisclosed partner since November 2023) and milestone/technology-access fees on AT292 (alpha-1 antitrypsin therapy, now SAR447537 following Sanofi's acquisition of Inhibrx). The deal is worth up to $11m ($7m upfront, up to $4m in commercial milestones), with Ligand also granted warrants over roughly one million shares at 67.39p.

Shedding Tetris, Sharpening the Model

Announced January 2025, the orderly wind-down of Tetris Pharma (the commercial subsidiary acquired in 2022, holding European rights to the Ogluo glucagon rescue pen) returned the Ogluo rights and removed a loss-making distribution operation, sharpening Arecor's identity as a formulation-development and licensing business.

The Numbers

For the year ended December 2025, cash and investments were £6.1m, up from £3.2m a year earlier, and revenue from continuing operations was £1.7m against £1.6m in 2024, with more than £1m attributed to three new formulation collaborations. Management has guided a base-case cash runway into 2027 (sustainability of operations into May 2027 on a base case). A July 2024 placing, subscription and retail offer raised approximately £6.4m at 90p per share.

Risks Worth Weighing

AT278 and AT247 have only completed Phase I; a Phase 2 study for AT278 is guided but hasn't produced efficacy data. Financing risk is material — the group is loss-making and has repeatedly relied on royalty monetisation and equity raises. Partner concentration is a structural exposure, as much of the company's value depends on decisions taken by Sequel Med Tech, Ligand, Sanofi and other collaborators outside Arecor's control.

What to Watch Next

The filing of the AT278 IND and initiation of its Phase 2 study, both guided for 2026. Any expansion of the Sequel Med Tech relationship into a broader commercialisation agreement. A partnering deal for AT247. Commercial milestone receipts under the Ligand arrangement. New Arestat formulation collaborations or their conversion into licences.